A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease
Phase 2
Terminated
- Conditions
- Alzheimer Disease
- Interventions
- Drug: REM0046127 Low DoseDrug: PlaceboDrug: REM0046127 High Dose
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- reMYND
- Target Recruit Count
- 14
- Registration Number
- NCT05478031
- Locations
- 🇪🇸
Fundacion ACE, Barcelona, Spain
🇳🇱BRC Amsterdam, Amsterdam, Netherlands
🇪🇸FISEVI Hospital Universitario Virgen del Rocio, Sevilla, Spain
A Phase 1 (First in Human) Randomized, Double-blind, Placebo-controlled SAD, MAD Study With Oral REM0046127
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- reMYND
- Target Recruit Count
- 77
- Registration Number
- NCT04672135
- Locations
- 🇦🇹
Medical University Vienna, Department of Clinical Pharmacology, Vienna, Austria
© Copyright 2025. All Rights Reserved by MedPath